Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Amit Bar‐Or et al.|New England Journal of Medicine|2016Cited by 2k
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalbán, Jerry S. Wolinsky, Stephen L. Hauser et al.|New England Journal of Medicine|2016Cited by 1.9k
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s diseasePaulo Fontoura, Susanne Ostrowitzki, Robert Lasser et al.|Alzheimer s Research & Therapy|2017Cited by 568
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Anna Santacruz et al.|The Lancet Neurology|2025Cited by 39